Eftrenonacog alfa

Drug Profile

Eftrenonacog alfa

Alternative Names: Alprolix; BIIB-029; Coagulation factor IX recombinant immunoglubulin G1 fusion protein; Factor IX-Fc; FIX-Fc; Recombinant factor IX Fc; rFIXFc

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer Bioverativ; Swedish Orphan Biovitrum
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 02 Feb 2017 Efficacy and adverse events data from the phase III KIDS B-LONG trial in Haemophilia B released by Swedish Orphan Biovitrum
  • 01 Feb 2017 Biogen has separated its Haemophilia Business under a new company Bioverativ
  • 01 Feb 2017 Launched for Haemophilia B (In adolescents, In children, In infants, In neonates, In adults) in Switzerland, Iceland, Norway, and Liechtenstein (IV) before February 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top